PHARVARIS N.V. EO -12 (9EN) - Total Liabilities
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has total liabilities worth €30.18 Million EUR (≈ $35.28 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is PHARVARIS N.V. EO -12 growing its equity to track the company's year-over-year net asset growth rate.
PHARVARIS N.V. EO -12 - Total Liabilities Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's total liabilities have evolved over time, based on quarterly financial data.
PHARVARIS N.V. EO -12 Competitors by Total Liabilities
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pebblebrook Hotel Trust
NYSE:PEB
|
USA | $2.77 Billion |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
China | CN¥675.50 Million |
|
Peugeot Invest SA
PA:PEUG
|
France | €1.19 Billion |
|
Grand City Properties SA
F:GYC
|
Germany | €5.57 Billion |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
China | CN¥6.71 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$7.98 Million |
|
Suning Commerce Group Co Ltd
SHE:002024
|
China | CN¥99.66 Billion |
|
Browave
TWO:3163
|
Taiwan | NT$887.78 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down PHARVARIS N.V. EO -12's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of PHARVARIS N.V. EO -12.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHARVARIS N.V. EO -12's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual total liabilities of PHARVARIS N.V. EO -12 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €30.18 Million ≈ $35.28 Million |
+27.81% |
| 2024-12-31 | €23.61 Million ≈ $27.61 Million |
+61.23% |
| 2023-12-31 | €14.65 Million ≈ $17.12 Million |
-20.72% |
| 2022-12-31 | €18.47 Million ≈ $21.60 Million |
+158.85% |
| 2021-12-31 | €7.14 Million ≈ $8.34 Million |
-- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more